In this phase II study, Lytix's lead drug candidate LTX-315 (named VP-315 in Verrica's study) has been tested in basal cell carcinoma patients. BCC is the most common type of cancer worldwide, with 3-4 million annual incidents in the US alone, and the global market is estimated to be USD 11.5 billion annually within 2028.  

"We're very excited for the coming topline results from Verrica. Skin cancer is one of the largest cancer indications worldwide and still growing. We strongly believe that our oncolytic molecules have the potential to contribute to the treatment of several cancer indications in the future", says CEO Dr. Øystein Rekdal.

Lytix will update the market shortly following the announcement from Verrica, and will hold a webcast on Thursday, August 15 at 11:00 CET (link will be accessible through Overview - Lytix Biopharma (https://lytixbiopharma.com/investors/overview.html) and included in a stock release on the publication date).

You can read the detailed press release from Verrica here: https://verrica.com/press_release/verrica-pharmaceuticals-to-report-second-quarter-financial-results-and-release-preliminary-topline-results-from-part-2-of-phase-2-trial-of-vp-315-for-the-treatment-of-basal-cell-carcinoma-on-august-14/  
Sign up to the presentation by Verrica on this link: https://viavid.webcasts.com/starthere.jsp?ei=1678543&tp_key=8db298d3d3  

In addition to Verrica's study in patients with BCC, Lytix has an ongoing study (ATLAS-IT-05) in late-stage skin melanoma patients and is starting another study in early-stage melanoma patients this summer at Oslo University Hospital (Radiumhospitalet).

For more information, please contact:
Dr. Øystein Rekdal, CEO
oystein.rekdal@lytixbiopharma.com
+47 975 73 358

Gjest Breistein, CFO
gjest.breistein@lytixbiopharma.com
+47 952 60 512

About Lytix
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, LTX-315, is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy.

About Verrica Pharmaceuticals
Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, YCANTH[®] (cantharidin), became the first treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is also developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com (https://connect.notified.com/Tracker?data=kHj8F5sIDudb3ajufead_r66pyRvNk8OgAbmDMGkwSnY47w7ZeavfvFOdj4alPhoWdL7zkjmwJ4Z8GQmeEMHjg==000194732737).